Clinical Trial: A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia

U.S., Dec. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07255846) titled 'A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia' on Nov. 14.

Brief Summary: This is a Phase 1a/1b, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of TER-1754 (a novel AKT1 inhibitor) in patients with HHT.

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: Hereditary Hemorrhagic Telangiectasia (HHT)

Intervention: DRUG: TER-1754

QD or BID, orally in 28-day cycles

DRUG: Placebo

Number of tablets will be confirmed post Phase 1a

DRUG: TER-1754

Phase 1b dose to be determined post Phase 1a

Recruitment Status: NOT_YET_RECR...